Claritas Pharmaceuticals now has exclusive worldwide rights to develop and market R-107 — a liquid form of nitric oxide — for the treatment of pulmonary diseases such as pulmonary arterial hypertension (PAH), acute respiratory distress syndrome (ARDS), and persistent pulmonary hypertension of the newborn (PPHN). In its announcement…
PhaseBio Pharmaceuticals has voluntarily ended the Phase 2b trial testing its investigational pulmonary arterial hypertension (PAH) therapy pemziviptadil (PB1046), due to the impact of the COVID-19 pandemic on medicine manufacturing, associated supply, and enrollment rates. The company said it would conduct an analysis of the trial’s results and,…
The use of the INOpulse combination drug-device therapy demonstrated a clinically meaningful reduction in pulmonary vascular resistance (PVR) — a measure of the internal resistance to blood flow within the lung arteries — in people with pulmonary hypertension (PH) associated with sarcoidosis (PH-Sarc). That’s according to top-line data…
Aerovate Therapeutics is starting a Phase 2b/3 clinical trial that will test AV-101, the company’s experimental inhaled formulation of imatinib, in people with pulmonary arterial hypertension (PAH). “We are excited and humbled to initiate this Phase 2b/Phase 3 trial of AV-101. Starting enrollment represents an important milestone for Aerovate Therapeutics and…
Aerami Therapeutics, a biopharmaceutical company focused on developing inhaled therapies for severe respiratory diseases — including pulmonary arterial hypertension (PAH) — has entered into a merger agreement with FoxWayne Enterprises Acquisition, a special purpose acquisition company (SPAC). The goal of this merger is to accelerate the development of…
The presence of specific patterns called centrilobular ground-glass opacifications (cGGOs) in high-resolution computed tomography (HRCT) lung scans is associated with a two-year higher risk of death in people with idiopathic pulmonary arterial hypertension (IPAH), according to a small study in Poland. These findings suggest that chest HRCT data could…
Beyond Air has announced that it is not expecting the U.S. Food and Drug Administration (FDA) to approve its LungFit PH device to treat persistent pulmonary hypertension of the newborn (PPHN) before the end of the year. Beyond Air filed an application with the FDA in late…
Pulmonary thromboendarterectomy (PTE) quickly and significantly improved blood flow dynamics and right-sided heart function in people with chronic thromboembolic pulmonary hypertension (CTEPH), with the surgery’s benefits sustained over the long term, a small study shows. Notably, right ventricular (RV) free wall strain, an indirect and non-invasive measure of…
A new study highlights the predictive utility of hypochromic erythrocytes — red blood cells that have decreased levels of hemoglobin (the oxygen carrier) — in patients with pulmonary arterial hypertension (PAH). The increased presence of these erythrocytes was shown to be an independent predictor of both mortality and shorter…
An orally available small molecule, BI113823, successfully reversed the progression of severe, advanced pulmonary arterial hypertension (PAH) in a rat model, a study demonstrated. The experimental medicine lowered pulmonary blood pressure, reduced blood vessel thickening, suppressed inflammatory responses, and prevented right heart failure and death. These findings support the…
Elevated levels of three blood proteins — AMBP, LPL and glyoxalase I — may help identify and distinguish people with pulmonary hypertension linked to heart failure with preserved ejection fraction, called HFpEF-PH, from those with pulmonary arterial hypertension or PAH, a study suggests. Differentiating between the two is key,…
The blood levels of two molecules involved in vascular remodeling, a hallmark feature of pulmonary arterial hypertension (PAH), may be used as noninvasive predictive biomarkers of the disease, a small study suggests. The study, “Fibrinolytic markers could be useful predictors of severity in patients with pulmonary…
Get regular updates to your inbox.